Analysis of radiation-induced angiosarcoma of the breast

被引:4
作者
Zemanova, M. [1 ,2 ]
Rauova, K. [3 ]
Boljesikova, E. [2 ]
Machalekova, K. [4 ,5 ]
Krajcovicova, I [1 ]
Lehotska, V [1 ,3 ]
Mikulova, M. [6 ]
Svec, J. [1 ]
机构
[1] Comenius Univ, Fac Med, Oncol Clin 1, SK-82510 Bratislava, Slovakia
[2] St Elizabeth Canc Inst, Dept Radiat Oncol, Bratislava, Slovakia
[3] St Elizabeth Canc Inst, Dept Radiodiagnost, Bratislava, Slovakia
[4] Slovak Med Univ, Dept Pathol, Bratislava, Slovakia
[5] St Elizabeth Canc Inst, Bratislava, Slovakia
[6] St Elizabeth Canc Inst, Dept Clin Oncol, Bratislava, Slovakia
来源
BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY | 2014年 / 115卷 / 05期
关键词
angiosarcoma; secondary malignancy; radiotherapy; treatment outcomes; CONTRALATERAL BREAST; RADIOTHERAPY; CANCER; RISK; WOMEN; CONSERVATION; PACLITAXEL; SARCOMAS; THERAPY;
D O I
10.4149/BLL_2014_062
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Breast angiosarcoma may occur de novo, or as a complication of radiation therapy, or chronic lymphedema secondary to axillary lymph node dissection for mammary carcinoma. Both primary and secondary angiosarcomas may present with bruise like skin discoloration, which may delay the diagnosis. Imaging findings are nonspecific. In case of high-grade tumours, MRI may be used effectively to determine lesion extent by showing rapid enhancement, nevertheless earliest possible diagnostics is crucial therefore any symptoms of angiosarcoma have to be carefully analysed. The case analysed here reports on results of 44-year old premenopausal woman who was treated for a T1N1M0 invasive ductal carcinoma. After a biopsy diagnosis of carcinoma, the patient underwent quadrantectomy with axillary lymph node dissection. She received partial 4 cycles of chemotherapy with adriamycin and cyclophosphamide, followed by radiation treatment. Thereafter, a standard postoperative radiotherapy was applied at our institution four months after chemotherapy (TD 46Gy in 23 fractions followed by a 10Gy electron boost to the tumour bed). Adjuvant chemotherapy was finished six months after operation, followed by tamoxifen. Follow up: no further complications were detected during regular check-ups. However, 12-years later, patient reported significant changes at breast region which was exposed to radiation during treatment of original tumour. In this article, we describe the clinical presentation, imaging and pathological findings of secondary angiosarcoma of the breast after radiotherapy (Fig. 2, Ref. 26). Text in PDF www.elis.sk.
引用
收藏
页码:307 / 310
页数:4
相关论文
共 28 条
[1]  
Abdalla I, 2000, CANCER J, V6, P266
[2]   Diagnosis and management of primary breast sarcoma [J].
Al-Benna, Sammy ;
Poggemann, Kerstin ;
Steinau, Hans-Ulrich ;
Steinstraesser, Lars .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (03) :619-626
[3]  
Body G, 1987, J GYNECOL OBSTET BIO, V16, P483
[4]   CANCER IN THE CONTRALATERAL BREAST AFTER RADIOTHERAPY FOR BREAST-CANCER [J].
BOICE, JD ;
HARVEY, EB ;
BLETTNER, M ;
STOVALL, M ;
FLANNERY, JT .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (12) :781-785
[5]   Postradiation vascular proliferations: an increasing problem [J].
Brenn, T ;
Fletcher, CDM .
HISTOPATHOLOGY, 2006, 48 (01) :106-114
[6]  
Brenn T, 2005, AM J SURG PATHOL, V29, P983
[7]  
ENZINGER FM, 1995, SOFT TISSUE TUMORS, P641
[8]   Vascular endothelial growth factor receptor-3 (VEGFR-3): A marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas [J].
Folpe, AL ;
Veikkola, T ;
Valtola, R ;
Weiss, SW .
MODERN PATHOLOGY, 2000, 13 (02) :180-185
[9]   Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: A population-based study [J].
Gao, X ;
Fisher, SG ;
Emami, B .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (04) :1038-1045
[10]   Angiosarcomas of the breast - A review of 70 cases [J].
Hodgson, Nicole C. ;
Bowen-Wells, Carol ;
Moffat, Fredrick ;
Franceschi, Dido ;
Avisar, Eli .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (06) :570-573